Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand
Open Access
- 1 December 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 12 (12) , e1006015
Abstract
Development of an effective vaccine against human cytomegalovirus (HCMV) is a need of utmost medical importance. Generally, it is believed that a live attenuated vaccine would best provide protective immunity against this tenacious pathogen. Here, we propose a strategy for an HCMV vaccine that aims at the simultaneous activation of innate and adaptive immune responses. An HCMV strain expressing the host ligand ULBP2 for the NKG2D receptor was found to be susceptible to control by natural killer (NK) cells, and preserved the ability to stimulate HCMV-specific T cells. Infection with the ULBP2-expressing HCMV strain caused diminished cell surface levels of MHC class I molecules. While expression of the NKG2D ligand increased the cytolytic activity of NK cells, NKG2D engagement in CD8+ T cells provided co-stimulation and compensated for lower MHC class I expression. Altogether, our data indicate that triggering of both arms of the immune system is a promising approach applicable to the generation of a live attenuated HCMV vaccine. Human cytomegalovirus (CMV) is a major cause of morbidity and mortality in congenitally infected newborns and immunocompromised individuals, indicating an utmost need for a vaccine to protect these vulnerable groups. Recent experimental studies in animal models, including non-human primates, have shown that attenuated CMVs trigger a potent immune response and are attractive vaccine candidates. However, an effective CMV vaccine is still not available. Here, we demonstrate that rational engineering of a live attenuated human CMV vaccine candidate is feasible. We equipped a CMV strain with an immunostimulatory molecule that is a ligand for an activating receptor present on both Natural Killer cells and CD8+ T cells. Moreover, we deleted several immunoevasins involved in downregulation of MHC class I molecules and of a ligand for Natural Killer cells in order to elicit stronger immune responses. In vitro assays using human immune cells and a first assessment in a humanized mouse model in vivo suggest that the generated CMV strain is attenuated and has the ability to induce a virus-specific immune response. Our study proposes this novel approach for the development of a rationally engineered CMV vaccine.Keywords
Funding Information
- Deutsches Zentrum für Infektionsforschung (07.804)
- Helmholtz-Gemeinschaft (VH-VI-424)
- European Research Council (322693)
- Ministry of Science, Education and Sports of Croatia (Centre of Excellence research grant CERVirVac)
This publication has 88 references indexed in Scilit:
- A dual function of NKG2D ligands in NK-cell activationEuropean Journal of Immunology, 2012
- Expansion of a unique CD57+NKG2Chinatural killer cell subset during acute human cytomegalovirus infectionProceedings of the National Academy of Sciences of the United States of America, 2011
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- Plasmacytoid Dendritic Cell Ablation Impacts Early Interferon Responses and Antiviral NK and CD8+ T Cell AccrualImmunity, 2010
- Granulocyte-Colony Stimulating Factor Reactivates Human Cytomegalovirus in a Latently Infected Humanized Mouse ModelCell Host & Microbe, 2010
- Innate immunity defines the capacity of antiviral T cells to limit persistent infectionJournal of Experimental Medicine, 2010
- Birth Prevalence and Natural History of Congenital Cytomegalovirus Infection in a Highly Seroimmune PopulationClinical Infectious Diseases, 2009
- A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infectionVaccine, 2009
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Modulation of natural killer cells by human cytomegalovirusJournal of Clinical Virology, 2008